Media

Oncopeptides publishes year-end report 2025

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Intervacc Year-end report January – December 2025

European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Oncopeptides – Invitation to presentation of the year-end report 2025

Intervacc announces change of CEO

Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team